750 Corporate Drive
107 articles with Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, investigational treatment for moderate-to-severe atopic dermatitis.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
Glenmark Pharmaceutical S.A. to Invest in New Translational Research Group at Biopôle Lausanne-Epalinges
The new discovery group will enhance current capabilities in translational research
Glenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
Glenmark Pharmaceuticals announced poster presentations of data from three clinical studies of Ryaltris™, an investigational fixed-dose combination nasal spray for seasonal allergic rhinitis (SAR), at the AAAAI/WAO Joint Congress in Orlando, Florida.
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada.
Glenmark Pharma Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
The GBR 830 Phase 2a study was a double-blind, placebo-controlled study in adults with moderate-to-severe atopic dermatitis that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830.
Glenmark Pharma Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
Glenmark Pharma today announced a presentation of preliminary biomarker findings from a Phase 1 study of GBR 1302.
Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken, OmniRat, OmniMouse and OmniFlic to discover fully human mono- and multispecific antibodies.
Glenmark Pharma Announces Top-Line Results From a Phase III Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis
Glenmark plans to submit the company's first NDA to the FDA for Ryaltris for the treatment of patients with SAR in the first quarter of 2018.
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.
Jaguar Subsidiary Napo Pharmaceuticals, Inc. And Glenmark Pharma Sign Agreement Returning Key Rights In 141 Countries To Napo, Solidifying Jaguar’s Global Commercial Control Of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug
Glenmark Pharma Reports Positive Data In A Phase IIa Study Of GBR 830 For The Treatment Of Patients With Atopic Dermatitis
Glenmark Pharma Enters Exclusive Agreement With Cyndea Pharma S.L. For Generic Soft-Gelatin Capsule Drug Products
Glenmark Pharma Licenses Small Molecule Oncology Compound From APC Therapeutics To Expand Immuno-Oncology Portfolio
Glenmark Pharma To Initiate Clinical Study For GBR 1342, Second Investigational New Drug From Immuno-Oncology Portfolio
Glenmark Pharma Initiates Clinical Investigation For GBR 310, Its Proposed Biosimilar Candidate For XOLAIR
Glenmark Pharma Reports Positive Results From A Phase III Trial Of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, In Seasonal Allergic Rhinitis